Literature DB >> 11269575

Lack of citalopram effect on oral digoxin pharmacokinetics.

F Larsen1, M Priskorn, K F Overø.   

Abstract

The effect of chronic administration of citalopram on the single oral dose pharmacokinetics of digoxin was evaluated in 11 healthy adult subjects in an open, one-way crossover study. Subjects received 1 mg digoxin on day 1. Serial blood samples and total urine were collected over 192 hours, followed by an 11-day washout period. On days 22 through 50, subjects received 40 mg citalopram once daily. On day 43, a single dose of 1 mg digoxin was coadministered; again, serial blood samples and total urine were collected over 192 hours after the digoxin dose. There were no statistically significant differences in any of the digoxin pharmacokinetic parameters (AUC(0-->24), AUC(0-->infinity), Cmax, tmax, t(1/2), CL/F, CLrenal, and Ae(0-->infinity)), and the 90% confidence intervals for treatment differences for the parameters (except for tmax) were all within 80% to 125%. Concomitant digoxin administration did not significantly affect citalopram pharmacokinetics. The treatment was well tolerated by all subjects; no serious adverse events and no clinically significant ECG changes were observed. These data suggest that it is unlikely that concomitantly administered citalopram would have any significant effect on serum digoxin concentrations in patients who are receiving chronic digoxin therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11269575     DOI: 10.1177/00912700122010041

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  5 in total

1.  A population-based assessment of the potential interaction between serotonin-specific reuptake inhibitors and digoxin.

Authors:  David N Juurlink; Muhammad M Mamdani; Alexander Kopp; Nathan Herrmann; Andreas Laupacis
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

2.  Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers.

Authors:  Natacha Lenuzza; Xavier Duval; Grégory Nicolas; Etienne Thévenot; Sylvie Job; Orianne Videau; Céline Narjoz; Marie-Anne Loriot; Philippe Beaune; Laurent Becquemont; France Mentré; Christian Funck-Brentano; Loubna Alavoine; Philippe Arnaud; Marcel Delaforge; Henri Bénech
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-03       Impact factor: 2.441

Review 3.  The clinical pharmacokinetics of escitalopram.

Authors:  Niranjan Rao
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.

Authors:  N Klein; J Sacher; T Geiss-Granadia; T Attarbaschi; N Mossaheb; R Lanzenberger; C Pötzi; A Holik; C Spindelegger; S Asenbaum; R Dudczak; J Tauscher; S Kasper
Journal:  Psychopharmacology (Berl)       Date:  2006-09-06       Impact factor: 4.530

5.  Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study.

Authors:  Nikolas Klein; Julia Sacher; Thomas Geiss-Granadia; Nilufar Mossaheb; Trawat Attarbaschi; Rupert Lanzenberger; Christoph Spindelegger; Alexander Holik; Susanne Asenbaum; Robert Dudczak; Johannes Tauscher; Siegfried Kasper
Journal:  Psychopharmacology (Berl)       Date:  2007-01-19       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.